Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and PK of Antaitavir in Chronic Hepatitis C
NCT04201275Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Dec 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of antaitavir hasophate in chronic hepatitis C (CHC) (4 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse Events, laboratory abnormalities and other abnormalities at 8 days, Antiviral Activity at 8 days and 5 more. Started Dec 2019; status: completed.
02
Drugs
antaitavir hasophate
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT04201275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201275.